In the global pharmaceutical industry, there were 65 private equity deals announced in Q2 2024, worth a total value of $5.2bn, according to GlobalData's Deals Database. The $4bn institutional buy-out (ibo) Vantive by Carlyle Group was the industry's largest disclosed deal. A thorough analysis of the disruptive themes and the Private Equity deal activity are included in GlobalData's Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, private equity deal activity increased by 37% in Q2 2024 compared with the previous quarter's total of $3.8bn and fell by 70% as compared to Q2 2023. Related deal volume decreased by 11% in Q2 2024 versus the previous quarter and was 32% lower than in Q2 2023.
Notably, healthcare-related deals accounted for a 40% share of the global pharmaceutical industry’s private equity deal activity in Q2 2024, up 44% over the previous quarter.
The top-ranked financial advisors supporting these private equity deals in H1 2024 were KeyCorp; Avendus Capital; Barclays with 3, 2, 2 deals respectively.
The top-ranked legal advisors supporting these private equity deals in H1 2024 were Kirkland & Ellis; McDermott Will & Emery; Latham & Watkins with 9, 6, 5 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q2 2024 – Thematic Intelligence, buy the report here.
